Law360, New York (February 04, 2011, 2:39 PM ET) -- Insurer Health Net Inc. has fired the latest salvo against Solvay Pharmaceuticals Inc., filing a putative class action over the company's alleged anti-competitive scheme to block generic versions of the company's hormone drug AndroGel from entering the market.
Solvay and its subsidiary Unimed Pharmaceuticals Inc. unfairly deprived Health Net's subscribers and other indirect purchasers of the option of choosing between the brand name AndroGel and a cheaper generic, according to a complaint filed Wednesday in the U.S. District Court for the Northern District of Georgia within...
Health Net Hits Solvay With AndroGel Antitrust Action
To view the full article, take a free trial now.
